Advanced Biomed (NASDAQ:ADVB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Advanced Biomed (NASDAQ:ADVB) to a hold rating in a report published on Saturday morning.

Separately, Weiss Ratings raised shares of Advanced Biomed from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Advanced Biomed Price Performance

Shares of Advanced Biomed stock opened at $8.02 on Friday. Advanced Biomed has a 1 year low of $3.61 and a 1 year high of $24.23. The firm’s 50-day moving average is $7.32 and its 200 day moving average is $5.69. The stock has a market cap of $13.23 million, a price-to-earnings ratio of 1.66 and a beta of -0.41.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Advanced Biomed stock. BlackRock Inc. purchased a new stake in shares of Advanced Biomed Inc. (NASDAQ:ADVB) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 59,944 shares of the company’s stock, valued at approximately $186,000. BlackRock Inc. owned approximately 3.63% of Advanced Biomed at the end of the most recent reporting period.

About Advanced Biomed

Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Through the enrichment, capture, and identification of circulating tumor cells and related tumor marker cells in the field of liquid biopsy, we aim to provide cancer patients with rapid and affordable assay products and services. These services include early screening and detection, diagnosis and staging, treatment selection, and patient outcome interventions for cancer. We are a holding company incorporated in the State of Nevada.